MEDA seeks marketing authorization for Zyclara in Europe

Jun 23 2011

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

MEDA: The marketing authorization application for the patented product Zyclara (imiquimod 3.75% cream) has been filed with the European Medicines Agency (EMA). Zyclara has been documented for once-daily topical treatment of actinic keratosis (AK).

Zyclara expands the treatment area to the full face or balding scalp and could become a first line therapy for AK. More than 1,400 patients have been included in seven clinical studies.

"Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin", says Anders Lönner, CEO of Meda.